No quarterly revenue total was found in PMV PHARMACEUTICALS, INC.'s SEC filings.
PMV Pharmaceuticals, Inc. (PMVP) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$14.6 million. As of Jun 30, 2026 it held $79.4 million in cash and investments and $217,000 in total debt.
Revenue
—
Net income
$-18.09M
+14.7% vs year-ago quarter
Operating cash flow
$-14.58M
+20.4% vs year-ago quarter
Free cash flow
$-14.58M
+20.4% vs year-ago quarter
EPS
$-0.34
+17.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
53.46M
+0.9% vs year-ago quarter
Net cash
$79.21M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PMVP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1699382
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$18.9M | -$19.0M | -$19.2M | -$22.5M | -$22.9M |
| Net income | -$18.1M | -$18.0M | -$18.0M | -$21.1M | -$21.2M |
| Diluted EPS | -$0.34 | -$0.34 | -$0.34 | -$0.40 | -$0.41 |
| Operating cash flow | -$14.6M | -$19.7M | -$17.2M | -$19.8M | -$18.3M |
| Free cash flow | -$14.6M | -$19.7M | -$17.2M | -$19.8M | -$18.3M |
| Total assets | $82.1M | $96.6M | $116.6M | $133.8M | $152.9M |
| Total liabilities | $10.6M | $8.6M | $11.8M | $12.8M | $12.2M |
| Stockholders' equity | $71.5M | $88.0M | $104.7M | $121.0M | $140.6M |
| Cash and investments | $79.4M | $93.5M | $112.9M | $129.2M | $148.3M |
| Total debt | $217,000 | $293,000 | $838,000 | $931,000 | $1.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 5, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 2, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Other events
|
Aug 31, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2026 | Jun 4, 2026 |
All 390 PMV Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.